نتایج جستجو برای: peginterferon alfa
تعداد نتایج: 19203 فیلتر نتایج به سال:
We read with great interest the article by Bazinet et al, which describes their findings from a phase II study of combination therapy tenofovir, peginterferon-alfa (pegIFN), and nucleic acid polymers (NAPs) REP-2139 or 2165 in hepatitis B e antigen–negative chronic B.1 The addition either NAP induced strong surface antigen (HBsAg) declines, resulting HBsAg undetectability ?50% patients. A signi...
BACKGROUND Chronic hepatitis C virus (HCV) infection is a cause of major complications in persons who are also infected with the human immunodeficiency virus (HIV). However, the treatment of HCV infection in such persons has been associated with a high rate of intolerance and a low rate of response. We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interfe...
Although newer and more effective treatments are now available for hepatitis C virus (HCV) infection, non-HCV viral hepatitis remains an important cause of liver disease, especially among HIV-infected individuals. Hepatitis B virus (HBV) is the leading cause of cirrhosis worldwide, and approximately one-quarter of patients with cirrhosis develop decompensated liver disease within 5 years. Initi...
BACKGROUND Primary analysis of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial showed long-term peginterferon therapy did not reduce complications in patients with chronic hepatitis C and advanced fibrosis or cirrhosis. AIM To assess the effects of long-term peginterferon therapy and disease progression on health-related quality of life (HRQOL), symptoms and sex...
BACKGROUND With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved clearance of hepatitis B surface antigen (HBsAg) at 6 months after treatment; however, reactivation of HBV DNA was observed in 36.3%. We investigated the predictive potential of HBsAg quantification...
BACKGROUND Approximately one-third of patients with chronic hepatitis C virus infection have persistently normal liver enzymes reflected by a normal serum alanine transaminase (ALT). Data with regards the efficacy and safety of treatment in patients chronically infected with Hepatitis C virus genotype 4 and normal serum ALT are limited. AIM To evaluate the efficacy and safety of peginterferon...
BACKGROUND/AIMS Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investiga...
UNLABELLED Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B surface antigen (HBsAg) clearance. Approximately 30% of hepatitis B e antigen (HBeAg)...
BACKGROUND & AIMS We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naïve or treatment-experienced patients with HCV genotype 3 infection. METHODS The study was conducted at 80...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید